| Issue Date | Title | Author(s) |
| 2018 | The Development and Characterisation of Everolimus Resistant Breast Cancer Cells | Hare, Stephen |
| 31-Oct-2018 | Differential expression of mTOR components in endometriosis and ovarian cancer: Effects of rapalogues and dual kinase inhibitors on mTORC1 and mTORC2 stoichiometry | Rogers‑Broadway, KR; Kumar, J; Sisu, C; Wander, G; Mazey, E; Jeyaneethi, J; Pados, G; Tsolakidis, D; Klonos, E; Grunt, T; Hall, M; Chatterjee, J; Karteris, E |
| 2010 | Differential expression of mTOR signalling components in drug resistance in ovarian cancer | Foster, H; Coley, HM; Goumenou, A; Pados, G; Harvey, AJ; Karteris, E |
| 21-Dec-2016 | Human C1q Induces Apoptosis in an Ovarian Cancer Cell Line via Tumor Necrosis Factor | Kaur, A; Sultan, SHA; Murugaiah, V; Pathan, AA; Alhamlan, F; Karteris, E; Kishore, U |
| 2014 | The human myometrium differentially expresses mTOR signalling components before and during pregnancy: Evidence for regulation by progesterone | Foster, HA; Davies, J; Pink, RC; Turkcigdem, S; Goumenou, A; Carter, DR; Saunders, NJ; Thomas, P; Karteris, E |
| 12-Sep-2019 | Kinase inhibitors and ovarian cancer | Katopodis, P; Chudasama, D; Wander, G; Sales, L; Kumar, J; Pandhal, M; Anikin, V; Chatterjee, J; Hall, M; Karteris, E |
| 2017 | MTOR function and therapeutic targeting in breast cancer | Hare, SH; Harvey, AJ |
